MAPT and Alzheimer disease: Notably, we also demonstrated that high baseline plasma NTA-tau levels are predictive of steeper reduction in cortical thickness and steeper cognitive decline, which highlights the suitability of this novel plasma biomarker for tracking the down effects of AD pathophysiology and disease progression.